10x Genomics (TXG) 10-Q 2 Nov 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2022	Oct. 31, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-39035
Entity Registrant Name	10x Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-5614458
Entity Address, Address Line One	6230 Stoneridge Mall Road
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	401-7300
Title of 12(b) Security	Class A common stock, par value $0.00001 per share
Trading Symbol	TXG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001770787
Common Class A
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		95,596,266
Common Class B
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		18,867,255

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 233,951	$ 587,447
Marketable securities	218,435	0
Restricted cash	508	1,028
Accounts receivable, net	83,549	85,254
Inventory	78,629	59,966
Prepaid expenses and other current assets	14,350	13,896
Total current assets	629,422	747,591
Property and equipment, net	257,694	169,492
Restricted cash	7,091	7,598
Operating lease right-of-use assets	71,095	60,918
Goodwill	4,511	4,511
Intangible assets, net	23,493	25,397
Other noncurrent assets	2,901	3,319
Total assets	996,207	1,018,826
Current liabilities:
Accounts payable	21,594	17,351
Accrued compensation and related benefits	28,214	31,626
Accrued expenses and other current liabilities	61,989	50,909
Deferred revenue	6,665	5,340
Operating lease liabilities	8,393	5,131
Total current liabilities	126,855	110,357
Accrued license fee, noncurrent	0	5,814
Operating lease liabilities, noncurrent	87,833	76,847
Other noncurrent liabilities	5,727	8,240
Total liabilities	220,415	201,258
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock	0	0
Common stock	2	2
Additional paid-in capital	1,793,388	1,680,865
Accumulated deficit	(1,012,106)	(863,321)
Accumulated other comprehensive income (loss)	(5,492)	22
Total stockholders’ equity	775,792	817,568
Total liabilities and stockholders’ equity	$ 996,207	$ 1,018,826

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 131,072	$ 125,297	$ 360,177	$ 346,960
Cost of revenue	30,377	24,518	83,559	46,493
Gross profit	100,695	100,779	276,618	300,467
Operating expenses:
Research and development	67,290	54,582	202,053	149,867
Selling, general and administrative	73,401	62,076	219,413	187,683
Accrued contingent liabilities	0	0	0	(660)
Total operating expenses	140,691	116,658	421,466	336,890
Loss from operations	(39,996)	(15,879)	(144,848)	(36,423)
Other income (expense):
Interest income	2,025	49	3,832	157
Interest expense	(114)	(219)	(351)	(649)
Other expense, net	(1,950)	(599)	(4,193)	(807)
Total other expense	(39)	(769)	(712)	(1,299)
Loss before provision for income taxes	(40,035)	(16,648)	(145,560)	(37,722)
Provision for income taxes	1,879	523	3,225	2,052
Net loss	$ (41,914)	$ (17,171)	$ (148,785)	$ (39,774)
Net loss per share, basic (in dollars per share)	$ (0.37)	$ (0.15)	$ (1.31)	$ (0.36)
Net loss per share, diluted (in dollars per share)	$ (0.37)	$ (0.15)	$ (1.31)	$ (0.36)
Weighted-average shares of common stock used in computing net loss per share, basic (in shares)	114,112,382	110,874,249	113,555,750	109,826,104
Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)	114,112,382	110,874,249	113,555,750	109,826,104

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (41,914)	$ (17,171)	$ (148,785)	$ (39,774)
Other comprehensive income (loss), net of tax:
Unrealized losses on available-for-sale marketable securities	(1,459)	0	(5,188)	0
Foreign currency translation adjustment	(68)	136	(326)	244
Other comprehensive income (loss), net of tax	(1,527)	136	(5,514)	244
Comprehensive loss	$ (43,441)	$ (17,035)	$ (154,299)	$ (39,530)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Common Class A	Common Class A Common Stock	Common Class A Additional Paid-in Capital
Beginning balance (in shares) at Dec. 31, 2020		108,485,909
Beginning balance at Dec. 31, 2020	$ 739,072	$ 2	$ 1,544,218	$ (805,098)	$ (50)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock related to equity awards (in shares)							1,102,618
Issuance of Class A common stock related to equity awards						$ 8,546		$ 8,546
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	16,253		16,253
Net loss	(11,551)			(11,551)
Other comprehensive income (loss)	98				98
Ending balance (in shares) at Mar. 31, 2021		109,588,527
Ending balance at Mar. 31, 2021	752,460	$ 2	1,569,059	(816,649)	48
Beginning balance (in shares) at Dec. 31, 2020		108,485,909
Beginning balance at Dec. 31, 2020	739,072	$ 2	1,544,218	(805,098)	(50)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(39,774)
Ending balance (in shares) at Sep. 30, 2021		111,537,448
Ending balance at Sep. 30, 2021	800,221	$ 2	1,644,897	(844,872)	194
Beginning balance (in shares) at Mar. 31, 2021		109,588,527
Beginning balance at Mar. 31, 2021	752,460	$ 2	1,569,059	(816,649)	48
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock related to equity awards (in shares)							1,151,392
Issuance of Class A common stock related to equity awards						16,194		16,194
Vesting of shares subject to repurchase, including early exercised options	42		42
Stock-based compensation	26,932		26,932
Net loss	(11,052)			(11,052)
Other comprehensive income (loss)	10				10
Ending balance (in shares) at Jun. 30, 2021		110,739,919
Ending balance at Jun. 30, 2021	784,586	$ 2	1,612,227	(827,701)	58
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock related to equity awards (in shares)							797,529
Issuance of Class A common stock related to equity awards						6,682		6,682
Vesting of shares subject to repurchase, including early exercised options	38		38
Stock-based compensation	25,950		25,950
Net loss	(17,171)			(17,171)
Other comprehensive income (loss)	136				136
Ending balance (in shares) at Sep. 30, 2021		111,537,448
Ending balance at Sep. 30, 2021	800,221	$ 2	1,644,897	(844,872)	194
Beginning balance (in shares) at Dec. 31, 2021		112,514,977
Beginning balance at Dec. 31, 2021	817,568	$ 2	1,680,865	(863,321)	22
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock related to equity awards (in shares)							761,373
Issuance of Class A common stock related to equity awards						7,826		7,826
Vesting of shares subject to repurchase, including early exercised options	32		32
Stock-based compensation	26,137		26,137
Net loss	(42,413)			(42,413)
Other comprehensive income (loss)	(2,465)				(2,465)
Ending balance (in shares) at Mar. 31, 2022		113,276,350
Ending balance at Mar. 31, 2022	806,685	$ 2	1,714,860	(905,734)	(2,443)
Beginning balance (in shares) at Dec. 31, 2021		112,514,977
Beginning balance at Dec. 31, 2021	817,568	$ 2	1,680,865	(863,321)	22
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(148,785)
Ending balance (in shares) at Sep. 30, 2022		114,428,502
Ending balance at Sep. 30, 2022	775,792	$ 2	1,793,388	(1,012,106)	(5,492)
Beginning balance (in shares) at Mar. 31, 2022		113,276,350
Beginning balance at Mar. 31, 2022	806,685	$ 2	1,714,860	(905,734)	(2,443)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock related to equity awards (in shares)							610,447
Issuance of Class A common stock related to equity awards						6,360		6,360
Vesting of shares subject to repurchase, including early exercised options	32		32
Stock-based compensation	36,419		36,419
Net loss	(64,458)			(64,458)
Other comprehensive income (loss)	(1,522)				(1,522)
Ending balance (in shares) at Jun. 30, 2022		113,886,797
Ending balance at Jun. 30, 2022	783,516	$ 2	1,757,671	(970,192)	(3,965)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Class A common stock related to equity awards (in shares)							541,705
Issuance of Class A common stock related to equity awards						$ 2,039		$ 2,039
Vesting of shares subject to repurchase, including early exercised options	32		32
Stock-based compensation	33,646		33,646
Net loss	(41,914)			(41,914)
Other comprehensive income (loss)	(1,527)				(1,527)
Ending balance (in shares) at Sep. 30, 2022		114,428,502
Ending balance at Sep. 30, 2022	$ 775,792	$ 2	$ 1,793,388	$ (1,012,106)	$ (5,492)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net loss	$ (148,785)	$ (39,774)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	18,847	15,337
Stock-based compensation expense	95,874	69,058
Loss on disposal of property and equipment	455	66
Amortization of premium and accretion of discount on marketable securities, net	665	0
Amortization of right-of-use assets	5,687	5,593
Changes in operating assets and liabilities:
Accounts receivable	1,673	(27,216)
Inventory	(19,761)	(21,349)
Prepaid expenses and other current assets	(2,457)	(1,220)
Other noncurrent assets	411	348
Accounts payable	6,082	12,191
Accrued compensation and other related benefits	(3,163)	11,868
Deferred revenue	1,845	1,221
Accrued contingent liabilities	0	(44,173)
Accrued expenses and other current liabilities	2,867	(2,545)
Operating lease liability	(4,566)	(2,498)
Other noncurrent liabilities	(3,003)	(4,085)
Net cash used in operating activities	(47,329)	(27,178)
Investing activities:
Acquisition of business, net of cash acquired	(1,500)	(5,451)
Purchases of property and equipment	(91,927)	(73,660)
Purchase of marketable securities	(282,871)	0
Proceeds from sales of marketable securities	41,401	0
Proceeds from maturities of marketable securities	17,182	0
Net cash used in investing activities	(317,715)	(79,111)
Financing activities:
Payments on financing arrangement	(5,409)	(5,028)
Issuance of common stock from exercise of stock options and employee stock purchase plan purchases	16,225	31,422
Net cash provided by financing activities	10,816	26,394
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(295)	316
Net decrease in cash, cash equivalents, and restricted cash	(354,523)	(79,579)
Cash, cash equivalents, and restricted cash at beginning of period	596,073	688,644
Cash, cash equivalents, and restricted cash at end of period	241,550	609,065
Supplemental disclosures of cash flow information:
Cash paid for interest	841	1,222
Cash paid for taxes	3,649	8,318
Noncash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	29,290	12,710
Right-of-use assets obtained in exchange for new operating lease liabilities	16,562	19,566
Contingent consideration payable from business acquisition	$ 1,500	$ 1,536

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Organization and Description of Business 10x Genomics, Inc. (the “Company”) is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company’s integrated solutions include the Company’s Chromium Controller, Chromium Connect and Chromium X Series instruments, which the Company refers to as “Chromium instruments,” the Company's Visium CytAssist instrument and the Company’s proprietary microfluidic chips, slides, reagents and other consumables for the Company's Chromium and Visium solutions, which the Company refers to as “consumables.” The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company was incorporated in the state of Delaware in July 2012 and began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Asia, Europe and North America. Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2021 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates. The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K filed with the SEC on February 18, 2022 (our "Annual Report").

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies There were no material changes in the Company's significant accounting policies during the three and nine months ended September 30, 2022, except as set forth below. See Note 2 – Summary of Significant Accounting Policies to the consolidated financial statements included in the Company's Annual Report, for information regarding the Company's significant accounting policies. Marketable Securities The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable securities, within current assets on the balance sheet. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in "Accumulated other comprehensive income (loss)," a component of stockholders’ equity, net of tax. Realized gains (losses) on the sale of marketable securities are determined using the specific-identification method and recorded in "Other expense, net" in the Consolidated Statements of Operations. The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in “Other expense, net,” and unrealized losses not related to credit losses are recognized in “Accumulated other comprehensive income (loss).” There are no allowances for credit losses for the periods presented. As of September 30, 2022, the gross unrealized losses on available-for-sale securities are related to market interest rate changes and not attributable to credit. Fair Value of Financial Instruments Cash and cash equivalents are comprised of money market funds and cash which are classified as Level 1 in the fair value hierarchy. Assets recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 - Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. The Company’s financial instruments consist of Level 1 and Level 2 assets. Where quoted prices are available in an active market, securities are classified as Level 1. Money market funds are classified as Level 1. Level 2 assets consist primarily of corporate bonds, asset backed securities, commercial paper, U.S. Government Treasury and agency securities, and debt securities in government-sponsored entities based upon quoted market prices for similar movements in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third party-data providers, including but not limited to, benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data. Revenue Recognition The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component. The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities including awards under the Company’s equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. Stock-Based Compensation The Company’s stock-based compensation expense relates to stock options, restricted stock units (“RSUs”), market-based performance stock awards ("PSAs") including performance stock options and performance RSUs granted pursuant to equity incentive plans and stock purchase rights under an Employee Stock Purchase Plan (“ESPP”). Stock-based compensation expense for its stock-based awards is based on their grant date fair value. The Company determines the fair value of RSUs based on the closing price of its stock, which is listed on the Nasdaq Stock Market LLC, at the date of the grant. The Company estimates the fair value of stock option awards under an equity incentive plan and stock purchase rights under an ESPP on the grant date using the Black-Scholes option-pricing model. The fair values of stock-based awards excluding PSAs are recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. The Company calculated the expected term using the simplified method, which is the mid-point between the vesting and contractual term. Due to the short trading period of the Company's stock, the Company has estimated volatility by reference to the historical volatilities of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled award. For PSAs, the Company derives the requisite service period for each separately vesting portion of the award using a Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using the accelerated attribution method commencing on the grant date. The derived service period is the median duration of the successful stock price paths to meet the respective escalating stock price thresholds as simulated in the Monte Carlo valuation model which uses assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the PSAs. If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring On August 3, 2022, the Company implemented a reduction in force plan in order to decrease costs and maintain a streamlined organization to support the business. Restructuring charges of $4.2 million associated with this plan, comprised primarily of severance-related costs, were recorded in the three months ended September 30, 2022. The following table is a summary of restructuring costs related to the restructuring as of September 30, 2022 (in thousands): Severance and Benefits Costs Stock-Based Compensation Expense Total Restructuring charge $ 3,600 $ 616 $ 4,216 Cash payments made (2,838) — (2,838) Non-cash charge — (616) (616) Balance at September 30, 2022 $ 762 $ — $ 762 Restructuring costs of $0.3 million, $1.4 million and $2.5 million were recorded in cost of revenue, research and development expense, and selling, general and administrative expense, respectively, in the Company's condensed consolidated statements of operations during the three months ended September 30, 2022. No additional restructuring charges are expected to be incurred and the restructuring activities are expected to be substantially completed by the end of the fourth quarter of 2022.

Other Financial Statement Infor

Other Financial Statement Information	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Statement Information	Other Financial Statement Information Available-for-sale Securities Available-for-sale securities at September 30, 2022 consisted of the following (in thousands): Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Fair Value Measurement Cash equivalents: Money market funds $ 198,852 $ — $ — $ 198,852 Level 1 Marketable securities: Corporate debt securities 158,491 — (3,634) 154,857 Level 2 Government debt securities 54,142 — (1,417) 52,725 Level 2 Asset-backed securities 10,990 — (137) 10,853 Level 2 Total available-for-sale securities $ 422,475 $ — $ (5,188) $ 417,287 As of December 31, 2021, the Company held $548.0 million in money market funds with no unrealized gains or losses. The contractual maturities of marketable securities as of September 30, 2022 were as follows (in thousands): Amortized Cost Fair Value Due in one year or less $ 130,206 $ 127,560 Due after one year to five years 93,417 90,875 Total marketable securities $ 223,623 $ 218,435 Inventory Inventory was comprised of the following (in thousands): September 30, December 31, Purchased materials $ 33,418 $ 31,954 Work in progress 26,157 14,052 Finished goods 19,054 13,960 Inventory $ 78,629 $ 59,966 Accrued Compensation and Related Benefits Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued payroll and related costs $ 3,797 $ 3,978 Employee stock purchase program liability 1,812 1,693 Accrued bonus 14,278 16,558 Accrued commissions 3,055 3,417 Accrued acquisition-related compensation 3,766 4,430 Accrued vacation 1,089 1,172 Other 417 378 Accrued compensation and related benefits $ 28,214 $ 31,626 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued legal and related costs $ 3,277 $ 2,425 Accrued license fee 6,119 6,214 Accrued royalties for licensed technologies 4,245 4,415 Accrued property and equipment 29,290 15,361 Accrued professional services 4,447 8,593 Product warranties 1,968 994 Customer deposits 1,161 954 Taxes payable 3,118 4,622 Accrued lab supplies 1,266 2,056 Other 7,098 5,275 Accrued expenses and other current liabilities $ 61,989 $ 50,909 Product Warranties Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): Nine Months Ended 2022 2021 Beginning of period $ 994 $ 399 Amounts charged to cost of revenue 3,590 2,113 Repairs and replacements (2,616) (1,688) End of period $ 1,968 $ 824 Revenue and Deferred Revenue As of September 30, 2022, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of instruments, was $9.4 million, of which approximately $6.6 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $9.4 million and $7.7 million as of September 30, 2022 and December 31, 2021, respectively, consisted of deferred revenue related to extended warranty service agreements. The following revenue recognized for the periods were included in contract liabilities as of December 31, 2021 and December 31, 2020 (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Deferred revenue recognized $ 1,043 $ 884 $ 3,940 $ 3,412 The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Instruments $ 20,899 $ 17,121 $ 50,064 $ 45,123 Consumables 108,107 106,117 303,991 296,342 Services 2,066 2,059 6,122 5,495 Total revenue $ 131,072 $ 125,297 $ 360,177 $ 346,960 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 United States $ 75,345 $ 68,440 $ 202,159 $ 182,747 Europe, Middle East and Africa 27,927 25,819 74,067 73,761 China 15,773 19,063 45,620 55,577 Asia-Pacific (excluding China) 9,791 10,187 32,334 29,822 North America (excluding United States) 2,236 1,788 5,997 5,053 Total revenue $ 131,072 $ 125,297 $ 360,177 $ 346,960

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Lease Agreements The Company leases office, laboratory, manufacturing and distribution space in various locations worldwide. On November 6, 2020, the Company entered into a Master Lease Agreement ("MLA") to lease additional office building space near the Company's Pleasanton, California headquarters. The MLA consists of various lease components, a few of which commenced in the nine months ended September 30, 2022. The sole outstanding component is expected to commence in 2023 and is expected to terminate on June 30, 2033. Total undiscounted payments for the lease component commencing in fiscal year 2023 will be $14.0 million with an expected lease term of 10.5 years. Future net lease payments related to the Company’s operating lease liabilities as of September 30, 2022 is as follows (in thousands): Operating Leases 2022 (excluding the nine months ended September 30, 2022) $ 2,424 2023 14,774 2024 14,891 2025 13,774 2026 14,481 Thereafter 61,452 Total lease payments $ 121,796 Less: imputed interest (25,570) Present value of operating lease liabilities $ 96,226 Operating lease liabilities, current $ 8,393 Operating lease liabilities, noncurrent 87,833 Total operating lease liabilities $ 96,226 The following table summarizes additional information related to operating leases as of September 30, 2022: September 30, December 31, 2021 Weighted-average remaining lease term 8.4 years 8.7 years Weighted-average discount rate 5.5 % 5.4 % Litigation The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. Nanostring On May 6, 2021, the Company filed suit against Nanostring Technologies, Inc. ("Nanostring") in the U.S. District Court for the District of Delaware alleging that Nanostring's GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the "GeoMx Action"). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company's claim of infringement of U.S. Patent No. 10,662,467. Nanostring filed its answer to the GeoMx Action on May 18, 2022. Discovery is in progress. A Markman hearing is scheduled for November 2022 and trial is scheduled for August 2023. On February 28, 2022, the Company filed a second suit against Nanostring in the U.S. District Court for the District of Delaware alleging that Nanostring's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe U.S. Patent Nos. 10,227,639 and 11,021,737 (the "CosMx Action"). On May 12, 2022, the Company filed an amended complaint in the CosMx Action additionally alleging that the CosMx products infringe U.S. Patent Nos. 11,293,051, 11,293,052 and 11,293,054. Nanostring filed its answer to the CosMx Action on May 26, 2022. Discovery is in progress. A Markman hearing is scheduled for May 2023 and trial is scheduled for June 2024. On August 16, 2022, Nanostring filed a counterclaim in the CosMx Action alleging that the Company's Visium products infringe U.S. Patent No. 11,377,689. The Company filed its answer to Nanostring's counterclaim in the CosMx Action on August 30, 2022. Discovery and trial are consolidated with the Company's claims against Nanostring in the CosMx Action. The Company believes Nanostring's counterclaim in the CosMx Action is meritless and intends to vigorously defend itself. On October 20, 2022, Nanostring filed a separate suit against the Company in the U.S. District Court for the District of Delaware alleging that the Company's Visium products also infringe U.S. Patent No. 11,473,142, a continuation of U.S. Patent No. 11,377,689 (the "Nanostring Action"). The Company has not yet responded. Discovery has not yet commenced and no case schedule has been set. The Company believes Nanostring's claim in the Nanostring Action is meritless and intends to vigorously defend itself. On March 9, 2022, the Company filed suit in the Munich Regional Court in Germany alleging that Nanostring's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe EP Patent No. 2794928B1 (the "Germany CosMx Action"). Nanostring filed its statement of defense to the Germany CosMx Action on August 26, 2022. A hearing on infringement is scheduled for March 2023 and a decision is expected around May 2023. On July 29, 2022, Nanostring filed a nullity action with the German Federal Patent Court challenging the validity of EP Patent No. 2794928B1. A preliminary decision in the nullity action is expected by February 2023. Vizgen In May 2022, the Company filed suit against Vizgen, Inc. ("Vizgen") in the U.S. District Court for the District of Delaware alleging that Vizgen’s MERSCOPE Platform and workflow and Vizgen’s Lab Services program, including associated instruments and reagents, infringe U.S. Patent Nos. 11,021,737, 11,293,051, 11,293,052, 11,293,054 and 11,299,767. On July 25, 2022, Vizgen filed a motion to dismiss the Company's claims for willful and indirect infringement, which the Court denied on September 19, 2022. Discovery is in progress. A Markman hearing is scheduled for July 2023 and trial is scheduled for July 2024. On August 30, 2022, Vizgen filed its answer and counterclaims alleging that the Company's forthcoming Xenium product infringes U.S. Patent No. 11,098,303. Vizgen also filed counterclaims alleging that the Company tortiously interfered with Vizgen's contractual and business relationship with Harvard and that the Company engaged in unfair practices under Massachusetts state law. The Company has not yet responded. The Company believes these claims are meritless and intends to vigorously defend itself. Parse On August 24, 2022, the Company filed suit against Parse Biosciences, Inc. ("Parse") in the U.S. District Court for the District of Delaware alleging that Parse’s Evercode Whole Transcriptomics and ATAC-seq products infringe U.S. Patent Nos. 10,155,981, 10,697,013, 10,240,197, 10,150,995, 10,619,207, and 10,738,357. On October 17, 2022, Parse filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Company has not yet filed its response. Discovery has not yet commenced and no case schedule has been set.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Capital Stock	Capital Stock As of September 30, 2022, the number of shares of Class A common stock and Class B common stock issued and outstanding were 95,561,247 and 18,867,255, respectively. The following table represents the number of shares of Class B common stock converted to shares of Class A common stock upon the election of the holders of such shares during the periods: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Class B common stocks converted to Class A common stock — — 779,210 2,400,000

Equity Incentive Plans

Equity Incentive Plans	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans	Equity Incentive Plans Stock-based Compensation The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cost of revenue $ 1,281 $ 878 $ 3,748 $ 2,183 Research and development 14,476 11,226 41,346 30,162 Selling, general and administrative 17,757 13,846 50,780 36,713 Total stock-based compensation expense $ 33,514 $ 25,950 $ 95,874 $ 69,058 Restricted Stock Units Restricted stock unit activity for the nine months ended September 30, 2022 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2021 1,298,244 $ 141.48 Granted 5,462,866 45.21 Vested (495,552) 114.08 Cancelled (454,836) 105.49 Outstanding as of September 30, 2022 5,810,722 $ 56.13 Stock Options Stock option activity for the nine months ended September 30, 2022 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2021 8,212,754 $ 29.28 Granted 1,803,411 54.01 Exercised (1,326,102) 9.43 Cancelled (339,147) 56.90 Outstanding as of September 30, 2022 8,350,916 $ 36.66 Market-based Performance Stock Awards (PSAs) In September 2022, the Company granted 709,025 PSAs including performance stock options and RSUs under the 2019 Plan to certain members of management, which are subject to the achievement of certain escalating stock price thresholds established by the Company's Board of Directors. The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $60, $80 and $105, respectively, calculated based on 20 consecutive days of trading at each respective threshold. The escalating stock price thresholds can be met any time prior to the fourth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. As of September 30, 2022, none of the escalating stock price thresholds had been met resulting in no shares vesting or becoming exercisable. Stock-based compensation expense recognized for these market-based awards was approximately $0.2 million for the three months ended September 30, 2022. The weighted-average grant date fair value of the PSAs was $22.55. 2019 Employee Stock Purchase Plan A total of 3,284,859 shares of Class A common stock were reserved for issuance under the 2019 Employee Stock Purchase Plan ("ESPP"). The price at which Class A common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. During the nine months ended September 30, 2022 and 2021, 91,871 and 30,980 shares of Class A common stock, respectively, were issued under the ESPP. No shares of Class A common stock were issued under the ESPP during the three months ended September 30, 2022 or 2021. As of September 30, 2022, there were 2,965,685 shares available for issuance in connection under the ESPP.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Stock options to purchase common stock 8,350,916 9,206,850 8,350,916 9,206,850 Restricted stock units 5,810,722 1,314,157 5,810,722 1,314,157 Shares committed under ESPP 74,835 29,178 74,835 29,178 Shares subject to repurchase — 25,000 — 25,000 Contingent restricted shares — 236,484 — 236,484 Total 14,236,473 10,811,669 14,236,473 10,811,669

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2021 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. The inputs into our judgments and estimates consider the economic implications of COVID-19 on our critical and significant accounting estimates.
Marketable Securities	Marketable Securities The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable securities, within current assets on the balance sheet. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in "Accumulated other comprehensive income (loss)," a component of stockholders’ equity, net of tax. Realized gains (losses) on the sale of marketable securities are determined using the specific-identification method and recorded in "Other expense, net" in the Consolidated Statements of Operations. The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in “Other expense, net,” and unrealized losses not related to credit losses are recognized in “Accumulated other comprehensive income (loss).” There are no allowances for credit losses for the periods presented. As of September 30, 2022, the gross unrealized losses on available-for-sale securities are related to market interest rate changes and not attributable to credit.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Cash and cash equivalents are comprised of money market funds and cash which are classified as Level 1 in the fair value hierarchy. Assets recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 - Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. The Company’s financial instruments consist of Level 1 and Level 2 assets. Where quoted prices are available in an active market, securities are classified as Level 1. Money market funds are classified as Level 1. Level 2 assets consist primarily of corporate bonds, asset backed securities, commercial paper, U.S. Government Treasury and agency securities, and debt securities in government-sponsored entities based upon quoted market prices for similar movements in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third party-data providers, including but not limited to, benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data.
Revenue Recognition	Revenue Recognition The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 45 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component. The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts.
Net Loss Per Share	Net Loss Per Share Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis. Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities including awards under the Company’s equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.
Stock-Based Compensation	Stock-Based Compensation The Company’s stock-based compensation expense relates to stock options, restricted stock units (“RSUs”), market-based performance stock awards ("PSAs") including performance stock options and performance RSUs granted pursuant to equity incentive plans and stock purchase rights under an Employee Stock Purchase Plan (“ESPP”). Stock-based compensation expense for its stock-based awards is based on their grant date fair value. The Company determines the fair value of RSUs based on the closing price of its stock, which is listed on the Nasdaq Stock Market LLC, at the date of the grant. The Company estimates the fair value of stock option awards under an equity incentive plan and stock purchase rights under an ESPP on the grant date using the Black-Scholes option-pricing model. The fair values of stock-based awards excluding PSAs are recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. The Company calculated the expected term using the simplified method, which is the mid-point between the vesting and contractual term. Due to the short trading period of the Company's stock, the Company has estimated volatility by reference to the historical volatilities of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled award. For PSAs, the Company derives the requisite service period for each separately vesting portion of the award using a Monte Carlo simulation model and the related compensation expense is recognized over the derived service period using the accelerated attribution method commencing on the grant date. The derived service period is the median duration of the successful stock price paths to meet the respective escalating stock price thresholds as simulated in the Monte Carlo valuation model which uses assumptions such as volatility, risk-free interest rate, cost of equity and dividend estimated for the performance period of the PSAs. If the related market condition is achieved earlier than its estimated derived service period, the stock-based compensation expense will be accelerated, and a cumulative catch-up expense will be recorded during the period in which the market condition is met.

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Summary of Restructuring Costs Related to Restructuring	The following table is a summary of restructuring costs related to the restructuring as of September 30, 2022 (in thousands): Severance and Benefits Costs Stock-Based Compensation Expense Total Restructuring charge $ 3,600 $ 616 $ 4,216 Cash payments made (2,838) — (2,838) Non-cash charge — (616) (616) Balance at September 30, 2022 $ 762 $ — $ 762

Other Financial Statement Inf_2

Other Financial Statement Information (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Marketable Securities	Available-for-sale securities at September 30, 2022 consisted of the following (in thousands): Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Fair Value Measurement Cash equivalents: Money market funds $ 198,852 $ — $ — $ 198,852 Level 1 Marketable securities: Corporate debt securities 158,491 — (3,634) 154,857 Level 2 Government debt securities 54,142 — (1,417) 52,725 Level 2 Asset-backed securities 10,990 — (137) 10,853 Level 2 Total available-for-sale securities $ 422,475 $ — $ (5,188) $ 417,287
Debt Securities, Available-for-sale	The contractual maturities of marketable securities as of September 30, 2022 were as follows (in thousands): Amortized Cost Fair Value Due in one year or less $ 130,206 $ 127,560 Due after one year to five years 93,417 90,875 Total marketable securities $ 223,623 $ 218,435
Schedule of Inventory	Inventory was comprised of the following (in thousands): September 30, December 31, Purchased materials $ 33,418 $ 31,954 Work in progress 26,157 14,052 Finished goods 19,054 13,960 Inventory $ 78,629 $ 59,966
Schedule of Accrued Compensation and Related Benefits	Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued payroll and related costs $ 3,797 $ 3,978 Employee stock purchase program liability 1,812 1,693 Accrued bonus 14,278 16,558 Accrued commissions 3,055 3,417 Accrued acquisition-related compensation 3,766 4,430 Accrued vacation 1,089 1,172 Other 417 378 Accrued compensation and related benefits $ 28,214 $ 31,626
Schedule of Accrued Expense and Other Current Liabilities	Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued legal and related costs $ 3,277 $ 2,425 Accrued license fee 6,119 6,214 Accrued royalties for licensed technologies 4,245 4,415 Accrued property and equipment 29,290 15,361 Accrued professional services 4,447 8,593 Product warranties 1,968 994 Customer deposits 1,161 954 Taxes payable 3,118 4,622 Accrued lab supplies 1,266 2,056 Other 7,098 5,275 Accrued expenses and other current liabilities $ 61,989 $ 50,909
Schedule of Changes in the Reserve for Product Warranties	Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): Nine Months Ended 2022 2021 Beginning of period $ 994 $ 399 Amounts charged to cost of revenue 3,590 2,113 Repairs and replacements (2,616) (1,688) End of period $ 1,968 $ 824
Schedule of Revenue of Recognized in Contract Liabilities	The following revenue recognized for the periods were included in contract liabilities as of December 31, 2021 and December 31, 2020 (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Deferred revenue recognized $ 1,043 $ 884 $ 3,940 $ 3,412
Schedule of Revenue by Source	The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Instruments $ 20,899 $ 17,121 $ 50,064 $ 45,123 Consumables 108,107 106,117 303,991 296,342 Services 2,066 2,059 6,122 5,495 Total revenue $ 131,072 $ 125,297 $ 360,177 $ 346,960
Schedule of Revenue by Geographic Location	The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 United States $ 75,345 $ 68,440 $ 202,159 $ 182,747 Europe, Middle East and Africa 27,927 25,819 74,067 73,761 China 15,773 19,063 45,620 55,577 Asia-Pacific (excluding China) 9,791 10,187 32,334 29,822 North America (excluding United States) 2,236 1,788 5,997 5,053 Total revenue $ 131,072 $ 125,297 $ 360,177 $ 346,960

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Summary of Company's Operating Lease Liabilities	Future net lease payments related to the Company’s operating lease liabilities as of September 30, 2022 is as follows (in thousands): Operating Leases 2022 (excluding the nine months ended September 30, 2022) $ 2,424 2023 14,774 2024 14,891 2025 13,774 2026 14,481 Thereafter 61,452 Total lease payments $ 121,796 Less: imputed interest (25,570) Present value of operating lease liabilities $ 96,226 Operating lease liabilities, current $ 8,393 Operating lease liabilities, noncurrent 87,833 Total operating lease liabilities $ 96,226
Summary of Additional Information Related to Operating Leases	The following table summarizes additional information related to operating leases as of September 30, 2022: September 30, December 31, 2021 Weighted-average remaining lease term 8.4 years 8.7 years Weighted-average discount rate 5.5 % 5.4 %

Capital Stock (Tables)

Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Common Stock Issued and Outstanding	The following table represents the number of shares of Class B common stock converted to shares of Class A common stock upon the election of the holders of such shares during the periods: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Class B common stocks converted to Class A common stock — — 779,210 2,400,000

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations	The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cost of revenue $ 1,281 $ 878 $ 3,748 $ 2,183 Research and development 14,476 11,226 41,346 30,162 Selling, general and administrative 17,757 13,846 50,780 36,713 Total stock-based compensation expense $ 33,514 $ 25,950 $ 95,874 $ 69,058
Summary of RSU activity	Restricted stock unit activity for the nine months ended September 30, 2022 is as follows: Restricted Stock Weighted-Average Outstanding as of December 31, 2021 1,298,244 $ 141.48 Granted 5,462,866 45.21 Vested (495,552) 114.08 Cancelled (454,836) 105.49 Outstanding as of September 30, 2022 5,810,722 $ 56.13
Summary of the Company's Stock Option Activity	Stock option activity for the nine months ended September 30, 2022 is as follows: Stock Options Weighted-Average Outstanding as of December 31, 2021 8,212,754 $ 29.28 Granted 1,803,411 54.01 Exercised (1,326,102) 9.43 Cancelled (339,147) 56.90 Outstanding as of September 30, 2022 8,350,916 $ 36.66

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Stock options to purchase common stock 8,350,916 9,206,850 8,350,916 9,206,850 Restricted stock units 5,810,722 1,314,157 5,810,722 1,314,157 Shares committed under ESPP 74,835 29,178 74,835 29,178 Shares subject to repurchase — 25,000 — 25,000 Contingent restricted shares — 236,484 — 236,484 Total 14,236,473 10,811,669 14,236,473 10,811,669

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Revenue recognition, payment due period	45 days

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring costs		$ 4,200	$ 762
Forecast
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 0
Cost of Revenue
Restructuring Cost and Reserve [Line Items]
Restructuring costs		300
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring costs		1,400
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs		$ 2,500

Restructuring - Restructuring C

Restructuring - Restructuring Costs Related to Restructuring (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Restructuring Reserve [Roll Forward]
Restructuring charge		$ 4,216
Cash payments made		(2,838)
Non-cash charge		(616)
Restructuring costs	$ 4,200	762
Severance and Benefits Costs
Restructuring Reserve [Roll Forward]
Restructuring charge		3,600
Cash payments made		(2,838)
Non-cash charge		0
Restructuring costs		762
Stock-Based Compensation Expense
Restructuring Reserve [Roll Forward]
Restructuring charge		616
Cash payments made		0
Non-cash charge		(616)
Restructuring costs		$ 0

Other Financial Statement Inf_3

Other Financial Statement Information - Available-for-Sale Securities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Marketable Securities [Line Items]
Total marketable securities	$ 223,623
Gross Unrealized Gains	0
Gross Unrealized Losses	(5,188)
Marketable securities, fair value	218,435
Total available-for-sale securities, amortized cost	422,475
Total available-for-sale securities, fair value	417,287
Money market funds | Level 1
Marketable Securities [Line Items]
Money market funds	198,852
Corporate debt securities | Level 2
Marketable Securities [Line Items]
Total marketable securities	158,491
Gross Unrealized Gains	0
Gross Unrealized Losses	(3,634)
Marketable securities, fair value	154,857
Government debt securities | Level 2
Marketable Securities [Line Items]
Total marketable securities	54,142
Gross Unrealized Gains	0
Gross Unrealized Losses	(1,417)
Marketable securities, fair value	52,725
Asset-backed securities | Level 2
Marketable Securities [Line Items]
Total marketable securities	10,990
Gross Unrealized Gains	0
Gross Unrealized Losses	(137)
Marketable securities, fair value	$ 10,853

Other Financial Statement Inf_4

Other Financial Statement Information - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Concentration Risk [Line Items]
Transaction price allocated to remaining performance obligations	$ 9,400
Deferred revenue	6,665	$ 5,340
Deferred revenue recognized	9,400	7,700
Money market funds | Level 1
Concentration Risk [Line Items]
Money market funds		$ 548,000
Products and Services, Excluding Grant Revenue
Concentration Risk [Line Items]
Deferred revenue	$ 6,600

Other Financial Statement Inf_5

Other Financial Statement Information - Contractual Maturities of Marketable Securities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Amortized Cost
Due in one year or less	$ 130,206
Due after one year to five years	93,417
Total marketable securities	223,623
Fair Value
Due in one year or less	127,560
Due after one year to five years	90,875
Total marketable securities	$ 218,435

Other Financial Statement Inf_6

Other Financial Statement Information - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Purchased materials	$ 33,418	$ 31,954
Work in progress	26,157	14,052
Finished goods	19,054	13,960
Inventory	$ 78,629	$ 59,966

Other Financial Statement Inf_7

Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and related costs	$ 3,797	$ 3,978
Employee stock purchase program liability	1,812	1,693
Accrued bonus	14,278	16,558
Accrued commissions	3,055	3,417
Accrued acquisition-related compensation	3,766	4,430
Accrued vacation	1,089	1,172
Other	417	378
Accrued compensation and related benefits	$ 28,214	$ 31,626

Other Financial Statement Inf_8

Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued legal and related costs	$ 3,277	$ 2,425
Accrued license fee	6,119	6,214
Accrued royalties for licensed technologies	4,245	4,415
Accrued property and equipment	29,290	15,361
Accrued professional services	4,447	8,593
Product warranties	1,968	994
Customer deposits	1,161	954
Taxes payable	3,118	4,622
Accrued lab supplies	1,266	2,056
Other	7,098	5,275
Accrued expenses and other current liabilities	$ 61,989	$ 50,909

Other Financial Statement Inf_9

Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning of period	$ 994	$ 399
Amounts charged to cost of revenue	3,590	2,113
Repairs and replacements	(2,616)	(1,688)
End of period	$ 1,968	$ 824

Other Financial Statement In_10

Other Financial Statement Information - Revenue Recognition (Details)	Sep. 30, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected period of revenue recognition	12 months

Other Financial Statement In_11

Other Financial Statement Information - Schedule of Revenue of Recognized in Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred revenue recognized	$ 1,043	$ 884	$ 3,940	$ 3,412

Other Financial Statement In_12

Other Financial Statement Information - Schedule of Revenue by Source (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from External Customer [Line Items]
Revenue	$ 131,072	$ 125,297	$ 360,177	$ 346,960
Instruments
Revenue from External Customer [Line Items]
Revenue	20,899	17,121	50,064	45,123
Consumables
Revenue from External Customer [Line Items]
Revenue	108,107	106,117	303,991	296,342
Services
Revenue from External Customer [Line Items]
Revenue	$ 2,066	$ 2,059	$ 6,122	$ 5,495

Other Financial Statement In_13

Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 131,072	$ 125,297	$ 360,177	$ 346,960
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	75,345	68,440	202,159	182,747
Europe, Middle East and Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	27,927	25,819	74,067	73,761
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	15,773	19,063	45,620	55,577
Asia-Pacific (excluding China)
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	9,791	10,187	32,334	29,822
North America (excluding United States)
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 2,236	$ 1,788	$ 5,997	$ 5,053

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - Pleasanton, California $ in Millions	Sep. 30, 2022 USD ($)
Loss Contingencies [Line Items]
Lease payment commencing 2023	$ 14
2023
Loss Contingencies [Line Items]
Weighted-average expected lease terms	10 years 6 months

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Company's Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Operating Leases
2022 (excluding the nine months ended September 30, 2022)	$ 2,424
2023	14,774
2024	14,891
2025	13,774
2026	14,481
Thereafter	61,452
Total lease payments	121,796
Less: imputed interest	(25,570)
Present value of operating lease liabilities	96,226
Operating lease liabilities, current	8,393	$ 5,131
Operating lease liabilities, noncurrent	87,833	$ 76,847
Total operating lease liabilities	$ 96,226

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Additional Information Related to Operating Leases (Detail)	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Weighted-average remaining lease term	8 years 4 months 24 days	8 years 8 months 12 days
Weighted-average discount rate	5.50%	5.40%

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail)	Sep. 30, 2022 shares
Common Class A
Class of Stock [Line Items]
Common stock shares issued (in shares)	95,561,247
Common stock shares outstanding (in shares)	95,561,247
Common Class B
Class of Stock [Line Items]
Common stock shares issued (in shares)	18,867,255
Common stock shares outstanding (in shares)	18,867,255

Capital Stock - Schedule of Com

Capital Stock - Schedule of Common Stock Issued and Outstanding (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Shares Converted From Class B to Class A
Conversion of Stock [Line Items]
Conversion of stock, shares converted (in shares)	0	0	779,210	2,400,000

Equity Incentive Plans - Record

Equity Incentive Plans - Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 33,514	$ 25,950	$ 95,874	$ 69,058
Cost of revenue
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	1,281	878	3,748	2,183
Research and development
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	14,476	11,226	41,346	30,162
Selling, general and administrative
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 17,757	$ 13,846	$ 50,780	$ 36,713

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of RSU Activity (Detail)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Restricted Stock Units
Restricted Stock Units, Beginning balance (in shares) | shares	1,298,244
Restricted Stock Units, Granted (in shares) | shares	5,462,866
Restricted Stock Units, Vested (in shares) | shares	(495,552)
Restricted Stock Units, Cancelled (in shares) | shares	(454,836)
Restricted Stock Units, Ending balance (in shares) | shares	5,810,722
Weighted-Average Grant Date Fair Value (per share)
Weighted-Average Grant Date Fair Value, Beginning balance (in dollars per share) | $ / shares	$ 141.48
Weighted-Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	45.21
Weighted-Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares	114.08
Weighted-Average Grant Date Fair Value, Cancelled (in dollars per share) | $ / shares	105.49
Weighted-Average Grant Date Fair Value, Ending balance (in dollars per share) | $ / shares	$ 56.13

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary of Company's Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Stock Options
Outstanding stock options, Beginning balance (in shares) | shares	8,212,754
Outstanding stock options - Granted (in shares) | shares	1,803,411
Outstanding stock options - Exercised (in shares) | shares	(1,326,102)
Outstanding stock options - Cancelled (in shares) | shares	(339,147)
Outstanding stock options, Ending balance (in shares) | shares	8,350,916
Weighted-Average Exercise Price
Weighted-average exercise price - Beginning balance (in dollars per share) | $ / shares	$ 29.28
Weighted-average exercise price - Granted (in dollars per share) | $ / shares	54.01
Weighted-average exercise price - Exercised (in dollars per share) | $ / shares	9.43
Weighted-average exercise price - Cancelled (in dollars per share) | $ / shares	56.90
Weighted-average exercise price - Ending balance (in dollars per share) | $ / shares	$ 36.66

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($) d $ / shares shares	Sep. 30, 2021 shares	Dec. 31, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units, granted (in shares)	5,462,866
Weighted average grant date fair value granted (in dollars per share) | $ / shares	$ 45.21
Market-based Performance Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation arrangement by predetermined share price consecutive | d	20
Share based payment arrangement recognized | $	$ 200
Weighted average grant date fair value granted (in dollars per share) | $ / shares	$ 22.55
Market-based Performance Awards | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of stock | $	$ 60
Market-based Performance Awards | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of stock | $	80
Market-based Performance Awards | Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of stock | $	$ 105
Performance Stock Options and Restricted stock Units | 2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units, granted (in shares)	709,025
Employee Stock | 2019 Plan | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement percent	85%
Employee Stock | 2019 Employee Stock Purchase Plan | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)	2,965,685		3,284,859
Shares issued in period for previously outstanding awards (in shares)	91,871	30,980
Employee Stock | Employee Stock Purchase Plan | Common Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)			0

Net Loss Per Share - Shares of

Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	14,236,473	10,811,669	14,236,473	10,811,669
Stock options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	8,350,916	9,206,850	8,350,916	9,206,850
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	5,810,722	1,314,157	5,810,722	1,314,157
Shares committed under ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	74,835	29,178	74,835	29,178
Shares subject to repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0	25,000	0	25,000
Contingent restricted shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0	236,484	0	236,484